Best Practice in the chemical characterisation of extracts used in pharmacological and toxicological research-The ConPhyMP-Guidelines.

Best Practice in the chemical characterisation of extracts used in pharmacological and toxicological research-The ConPhyMP-Guidelines.
复制标题

DOI:
10.3389/fphar.2022.953205
复制
发表时间:
2022
影响因子:
5.6
通讯作者:
Wang, Jia-Bo
Wang, Jia-Bo
中科院分区:
医学2区
文献类型:
--
作者:
Heinrich, Michael;Jalil, Banaz;Abdel-Tawab, Mona;Echeverria, Javier;Kulic, Zarko;McGaw, Lyndy J.;Pezzuto, John M.;Potterat, Olivier;Wang, Jia-Bo

文献摘要

参考文献

被引文献

相似文献

背景:对药用植物及其提取物的研究不同于对单一化合物的研究。从植物、藻类、真菌、地衣或动物中获得的提取物提出了一些独特的挑战:它们是活性、部分活性和非活性物质的多组分混合物,并且活性通常不会施加在单一目标上。它们的组成取决于制备方法和使用的植物材料。这种复杂性和可变性影响药理学、毒理学和临床研究的再现性和解释。 目的:该项目制定了最佳实践指南,以确保使用药用植物提取物的研究的再现性和准确解释。重点是药理学,毒理学和临床/干预研究中使用的草药提取物。具体而言,基于共识的声明侧重于定义以下要求:1)描述这些研究中使用的植物材料/草药物质、草药提取物和草药产品,以及2)以可重现和透明的方式对这些研究中使用的植物提取物进行植物化学分析并报告。 过程和方法:我们通过以下过程制定了指南:1)三种主要类型提取物之间的区别(提取物类型A、B和C),最初由主要作者(MH)概念化,领导了项目的开发; 2)在药用植物研究人员中进行调查,以收集全球观点,机会,以及在不同的实验室基础设施下表征药用植物提取物所面临的总体挑战。调查答复对制定准则至关重要,并由核心小组进行审查; 3)由9名专家组成的核心小组每月举行会议,通过德尔菲程序制定准则;以及。4)经核心小组核可的准则最后草案也分发给一个由20名专家组成的扩大咨询小组,其中包括许多期刊编辑,以征求反馈意见和批准。 结果:主要成果是“药用植物提取物植物化学表征共识声明”(ConPhyMP),该声明定义了报告起始植物材料的最佳实践以及用于定义此类研究中使用的植物提取物化学成分的化学方法。该清单旨在为药用植物研究的作者以及同行评审员和编辑评估此类研究以供出版提供指导。
Background: Research on medicinal plants and extracts derived from them differs from studies performed with single compounds. Extracts obtained from plants, algae, fungi, lichens or animals pose some unique challenges: they are multicomponent mixtures of active, partially active and inactive substances, and the activity is often not exerted on a single target. Their composition varies depending on the method of preparation and the plant materials used. This complexity and variability impact the reproducibility and interpretation of pharmacological, toxicological and clinical research. Objectives: This project develops best practice guidelines to ensure reproducibility and accurate interpretations of studies using medicinal plant extracts. The focus is on herbal extracts used in pharmacological, toxicological, and clinical/intervention research. Specifically, the consensus-based statement focuses on defining requirements for: 1) Describing the plant material/herbal substances, herbal extracts and herbal medicinal products used in these studies, and 2) Conducting and reporting the phytochemical analysis of the plant extracts used in these studies in a reproducible and transparent way. The process and methods: We developed the guidelines through the following process: 1) The distinction between the three main types of extracts (extract types A, B, and C), initially conceptualised by the lead author (MH), led the development of the project as such; 2) A survey among researchers of medicinal plants to gather global perspectives, opportunities, and overarching challenges faced in characterising medicinal plant extracts under different laboratory infrastructures. The survey responses were central to developing the guidelines and were reviewed by the core group; 3) A core group of 9 experts met monthly to develop the guidelines through a Delphi process; and. 4) The final draft guidelines, endorsed by the core group, were also distributed for feedback and approval to an extended advisory group of 20 experts, including many journal editors. Outcome: The primary outcome is the “Consensus statement on the Phytochemical Characterisation of Medicinal Plant extracts“ (ConPhyMP) which defines the best practice for reporting the starting plant materials and the chemical methods recommended for defining the chemical compositions of the plant extracts used in such studies. The checklist is intended to be an orientation for authors in medicinal plant research as well as peer reviewers and editors assessing such research for publication.
DOI: 10.1001/jama.276.8.637
发表时间: 1996-08-28
影响因子: 120.7
作者:
Begg, C;Cho, M;Stroup, DF
通讯作者: Stroup, DF
DOI: 10.1007/s11101-019-09625-z
发表时间: 2020-10-01
影响因子: 7.7
作者:
Upton, Roy;David, Bruno;Glasl, Sabine
通讯作者: Glasl, Sabine
DOI: 10.1371/journal.pmed.0020124
发表时间: 2005-08-01
期刊: PLOS MEDICINE
影响因子: 15.8
作者:
Ioannidis, JPA
通讯作者: Ioannidis, JPA
DOI: 10.1016/j.jep.2019.112230
发表时间: 2020-01-10
影响因子: 5.4
作者:
Heinrich, Michael;Appendino, Giovanni;Viljoen, Alvaro
通讯作者: Viljoen, Alvaro
DOI: 10.1177/10731911211060298
发表时间: 2023-04
期刊: ASSESSMENT
影响因子: 3.8
作者:
Heinrich, Manuel;Geiser, Christian;Zagorscak, Pavle;Burns, G. Leonard;Bohn, Johannes;Becker, Stephen P.;Eid, Michael;Beauchaine, Theodore P.;Knaevelsrud, Christine
通讯作者: Knaevelsrud, Christine